Resource Library

Prevention with PURPOSE

This presentation, delivered by Dr Linda-Gail Bekker at IAS 2025, provides an overview of PURPOSE 1 and 2 lenacapavir clinical trial results as well as special considerations for administration to different populations and drug-drug interactions.

Research

Empowering Women’s PrEP Choices: Qualitative Insights into Long-Acting PrEP Preferences and Decision-Making during Pregnancy and Breastfeeding in South Africa and Botswana

This article from AIDS and Behavior explores preferences for various long-acting PrEP modalities amongst pregnant and lactating people in Botswana and South Africa. It further examines participants’ HIV risk perception during pregnancy and breastfeeding, their perceived individual-level facilitators and barriers of each PrEP modality, and the support needed by participants for PrEP uptake and continuation.

Research, Service Delivery

“…this could be a noble idea and a game changer.” The Potential of a Dual Prevention Pill for HIV and Pregnancy Prevention among Adolescent Girls and Young Women in Zimbabwe

This article from PLOS Global Public Health describes the opinions of adolescent girls and young women and health care providers in Zimbabwe regarding the dual prevention pill (DPP), combining oral contraceptives with oral PrEP to simultaneously prevent unintended pregnancy and HIV.

Research

Dapivirine Vaginal Ring Early Market Access Vehicle (EMAV)

In response to the voices of adolescent girls and women who need more HIV prevention choices, The Global Fund (GF) and the Children Investment Fund Foundation (CIFF) have partnered to make dapivirine vaginal rings available in GF-supported countries through an early market access vehicle. See here for EMAV request form in English. For guidance on…

Financing & Costing, Service Delivery, Supply Chain Management

A Mixed-Method Study of Feasibility and Acceptability of the Dapivirine Vaginal Ring among Adolescent Girls and Young Women (AGYW) in Selected Zimbabwean Districts

This article from PLOS Global Public Health describes the results of a study assessing the acceptability and feasibility of introducing the dapivirine vaginal ring (DVR) as an HIV prevention method among young women in Zimbabwe and to assess motivations and barriers of DVR uptake among the target population.

Research, Service Delivery

Frequently Asked Questions about the Dual Prevention Pill

The Dual Prevention Pill (DPP) is a single, co-formulated, daily oral pill containing oral pre-exposure prophylaxis (PrEP) and combined oral contraception (COC) that prevents both HIV and pregnancy. The DPP will add to the contraceptive and HIV prevention toolbox and will be the first multi-purpose prevention technology (MPT) to go to market since male and…

Service Delivery

Developing and Introducing a Dual Prevention Pill- Oral PrEP & oral contraception for HIV and pregnancy prevention

A coalition of partners is developing a novel Dual Prevention Pill (DPP) for prevention of pregnancy and HIV acquisition in high-need countries. In East and Southern Africa — where the DPP is initially planned for introduction — 65 percent of new HIV infections are amongst women aged 15 and over, and 15 percent of women…

Community/Advocacy, Research

Preventing HIV in Women in Africa

This article from Nature Medicine discusses the evolving landscape of biomedical prevention technologies for women in Africa, their implementation and financing, as well as priorities for HIV prevention research in this setting.

Research

Safety and Drug Quantification of the Dapivirine Vaginal Ring and Oral Pre-Exposure Prophylaxis in Breastfeeding Mother–Infant Pairs (MTN-043): A phase 3B, open-label, randomised trial

This article from The Lancet HIV discusses the results of the Microbicide Trials Network (MTN)-043 trial, which assessed the safety of use of the dapivirine vaginal ring during breastfeeding amongst participants in Malawi, South Africa, Uganda, and Zimbabwe.

Research

MTN-020 ASPIRE

Archived from the MTN website before it was taken down. Archived MTN ASPIRE news page available here. Primary Objectives Determine the effectiveness of dapivirine (25 mg) administered in a silicone elastomer matrix vaginal ring (VR), when inserted once every 4 weeks, in preventing HIV-1 infection among healthy sexually active HIV-uninfected women Assess the safety of…